Originally published by our sister publication Pain Medicine News
New real-world outcomes research demonstrated the safety and healthcare resource advantages of ibuprofen injection (Caldolor, Cumberland Pharmaceuticals) over ketorolac in both adult and pediatric populations.
The study, published in Frontiers of Pain Research (Front Pain Res 24;5: doi: 10.3389/fpain.2024.1484948), “provides compelling evidence,” according to the company in a statement, that